Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States.

[1]  P. Clark,et al.  Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. , 2006, Urology.

[2]  F. Verhaegen.  Brachytherapy Physics (Second Edition) , 2006 .

[3]  Louis Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[4]  A. Renshaw,et al.  Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Butler,et al.  Myths and fallacies in permanent prostate brachytherapy. , 2003, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[6]  M. Kattan,et al.  The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[7]  M. Zelefsky,et al.  Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[8]  W. Butler,et al.  Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. , 2002, Urology.

[9]  R. Stock,et al.  Permanent seed implantation for localized adenocarcinoma of the prostate , 2002, Current urology reports.

[10]  W. Butler,et al.  Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. , 2002, International journal of radiation oncology, biology, physics.

[11]  F. Vicini,et al.  Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. , 2001, The Journal of urology.

[12]  A. D'Amico.  Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate cancer. , 2001, Cancer journal.

[13]  P. Scardino,et al.  Primary Gleason Pattern as a Predictor of Disease Progression in Gleason Score 7 Prostate Cancer: A Multivariate Analysis of 823 Men Treated With Radical Prostatectomy , 2001, The American journal of surgical pathology.

[14]  A. Renshaw,et al.  The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy. , 1999, International journal of radiation oncology, biology, physics.

[15]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[16]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[17]  J. Epstein.  The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. , 1998, Seminars in urologic oncology.

[18]  W Cavanagh,et al.  Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. , 1997, Seminars in surgical oncology.

[19]  H. Holm.  The history of interstitial brachytherapy of prostatic cancer. , 1997, Seminars in surgical oncology.

[20]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[21]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[22]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[23]  K. Wallner,et al.  Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[24]  M. Kattan,et al.  External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. , 2002, Brachytherapy.

[25]  W. Butler,et al.  Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. , 2001, Cancer journal.